Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06256-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Sara Oubari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Hufelandstra…. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Chromosomes, Human, Pair 1, Chromosome Aberrations. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Universitätsklinikum Essen.
Abstract (Originalsprache)
Systemic light-chain amyloidosis (AL) is an acquired protein misfolding disease characterized by deposition of immunoglobulin light-chain fibrils most often secreted from clonal plasma cells. In this retrospective study we analyzed the impact of iFISH aberrations on clinical characteristics and outcomes in 175 AL patients presented between 2015 and 2024. The most common aberrations were t(11;14) (57%), deletion 13q14 (33%), +1q21 (21%), hyperdiploidy (21%) and deletion 16q23 (17%). Significant elevations in dFLC levels were observed in patients with + 1q21 (median 407 vs. 213 mg/l, p = 0.04) and deletion 16q23 (median 476 vs. 204, p = 0.006). Only + 1q21 was associated with increased levels of cardiac biomarkers NTproBNP (median 9945 vs. 3538 pg/ml, p = 0.002) and hsTnT (median 110 vs. 53 ng/l, p = 0.002). This resulted in an increased proportion of patients with Mayo stage IIIb (53% vs. 26%, p = 0.01). Patients with + 1q21 had more advanced plasma cell disease ( p = 0.0004). Our study highlights for the first time + 1q21 as the key aberration associated with advanced cardiac and plasma cell disease. After 17 months of follow-up, overall survival was significantly worse in patients with + 1q21 treated with daratumumab (7.2 months vs. not reached, p = 0.006). Alternative therapeutic approaches such as CAR-T therapies or bispecific antibodies should be further investigated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Hufelandstraße 55, Essen, 45147, Germany.
- Interdisciplinary Amyloidosis Network, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Department of Cardiology and Angiology, University Hospital Frankfurt, Frankfurt am Main, Germany.
- Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Department of Neurology and Center for Translational Neuro- and Behavioral Science, University Hospital Essen, Essen, Germany.
- Department of Medical Genetics, MVZ Dr. Eberhard & Partner Dortmund, Dortmund, Germany.
Förderung
- Deutsche Forschungsgemeinschaft
- Universitätsklinikum Essen
Zitieren
APA
Oubari, S., Papathanasiou, M., Michel, L., Rassaf, T., Thimm, A., Hagenacker, T., Ehling, D., Wieczorek, S., Naser, E., Hegenbart, U., Schönland, S., Dührsen, U., Reinhardt, H. C., & Carpinteiro, A. (2025). Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival. Annals of Hematology. https://doi.org/10.1007/s00277-025-06256-7
Vancouver
Oubari S, Papathanasiou M, Michel L, Rassaf T, Thimm A, Hagenacker T, et al. Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival. Annals of Hematology. 2025. doi:10.1007/s00277-025-06256-7
BibTeX
@article{Oubari2025,
author = {Oubari, Sara and Papathanasiou, Maria and Michel, Lars and Rassaf, Tienush and Thimm, Andreas and Hagenacker, Tim and Ehling, Daniela and Wieczorek, Stefan and Naser, Eyad and Hegenbart, Ute and Schönland, Stefan and Dührsen, Ulrich and Reinhardt, Hans Christian and Carpinteiro, Alexander},
title = {Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06256-7}
}
EUVIMED